Fig. 4From: Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective studyResistance mechanisms clarified by patient in TKIs+SBRT (a) and single TKIs (b) groups (Gefitinib, Erlotinib, Afatinib and Icotinib). SBRT stereotactic body radiation therapy, TKIs tyrosine kinase inhibitorsBack to article page